NCT02166827View on ClinicalTrials.gov

Effects of a NeuroAD System, for the Treatment of Alzheimer Disease

NATerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Alzheimer's Disease
Interventions
DEVICE

NeuroAD

Synchronized TMS and cognitive stimulation to 6 brain areas.

DEVICE

Sham TMS+Cog

Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.

Trial Locations (1)

9103102

Shaare Zedek, Jerusalem

Sponsors

Lead Sponsor

Neuronix Ltd
All Listed Sponsors
lead

Neuronix Ltd

INDUSTRY

NCT02166827 - Effects of a NeuroAD System, for the Treatment of Alzheimer Disease | Biotech Hunter | Biotech Hunter